Cargando…
Agitation in Alzheimer's disease: Novel outcome measures reflecting the International Psychogeriatric Association (IPA) agitation criteria
INTRODUCTION: The 2017 European Union‐North American Clinical Trials in Alzheimer's Disease Task Force recommended development of clinician‐rated primary outcome measures for Alzheimer's disease (AD) agitation trials, incorporating International Psychogeriatric Association (IPA) criteria....
Autores principales: | De Mauleon, Adelaide, Ismail, Zahinoor, Rosenberg, Paul, Miller, David, Cantet, Christelle, O'Gorman, Cedric, Vellas, Bruno, Lyketsos, Constantine, Soto, Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292260/ https://www.ncbi.nlm.nih.gov/pubmed/34132461 http://dx.doi.org/10.1002/alz.12335 |
Ejemplares similares
-
Agitation in cognitive disorders: International Psychogeriatric Association
provisional consensus clinical and research definition
por: Cummings, Jeffrey, et al.
Publicado: (2015) -
On Agitation
Publicado: (1920) -
Changes in QTc Interval in the Citalopram for Agitation in Alzheimer's Disease (CitAD) Randomized Trial
por: Drye, Lea T., et al.
Publicado: (2014) -
A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer’s disease patients with agitation
por: Akil, Ayman, et al.
Publicado: (2015) -
The Fate of the Agitator
Publicado: (1918)